SMS Pharmaceuticals Limited — Results, 07-02-2026: Integrated Filing- Financial

SMS Pharma delivered strong consolidated Q3 FY26 results. Revenue from operations jumped 21.40% YoY to ₹210.45 Cr, driven by its core Active Pharmaceutical Ingredients (API) business. Net Profit after Tax climbed 28.67% YoY to ₹23.47 Cr, with EPS at ₹2.59 (vs ₹2.15 last year). Despite rising costs for materials, employee benefits, and finance, the company maintained strong profitability. The Board also approved investing up to ₹7 Cr in its subsidiary, SMS Peptides. Overall, the results reflect strong financial momentum.